Press Releases

Press Releases

    Date Title View
    01/03/19
    Summary ToggleHorizon Pharma plc and HemoShear Therapeutics Enter into Exclusive Drug Discovery Collaboration in Gout
    PDF Version
    12/27/18
    Summary ToggleHorizon Pharma plc Announces FDA Approval to Expand the Age Range for RAVICTI® (glycerol phenylbutyrate) Oral Liquid to Include Newborns
    PDF Version
    12/17/18
    Summary ToggleHorizon Pharma plc to Present at the 37th Annual J.P. Morgan Healthcare Conference
    PDF Version
    11/16/18
    Summary ToggleHorizon Pharma plc to Participate in Upcoming Conferences
    PDF Version
    11/07/18
    Summary ToggleHorizon Pharma plc Reports Third-Quarter Net Sales Growth of 20 Percent Driven by Orphan and Rheumatology Net Sales Growth of 25 Percent; Increases Full-Year 2018 Adjusted EBITDA Guidance
    11/02/18
    Summary ToggleThe Chicago Tribune Names Horizon Pharma plc a 2018 Top Workplace
    PDF Version
    10/29/18
    Summary ToggleHorizon Pharma plc Announces Presentation of Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab at 2018 American Academy of Ophthalmology (AAO) Annual Meeting
    PDF Version
    10/25/18
    Summary ToggleHorizon Pharma plc Presents Multiple Retrospective Analyses Showing Kidney Transplant Recipients Have Higher Rates of Gout and Increased Disease Severity
    PDF Version
    10/25/18
    Summary ToggleHorizon Pharma plc to Participate in Investor Conferences in November
    PDF Version
    10/22/18
    Summary ToggleHorizon Pharma plc Announces Multiple Data Presentations Highlighting the Growing Burden of Uncontrolled Gout at the 2018 ACR/ARHP Annual Meeting
    PDF Version
    Displaying 31 - 40 of 446 results